Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Anika Therapeutics, Inc. operates as an integrated orthopedic medicines company. The Company develops, manufactures, and commercializes therapeutic pain management solutions based on its proprietary hyaluronic acid (HA) technology. Anika Therapeutics markets its products worldwide.
Website: anikatherapeutics.com



Growth: Pretty weak revenue growth rate 7.5%, there is slowdown compared to average historical growth rates 8.5%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -45.2%. On average the margin is decreasing steadily. Gross margin is high, +61.3%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.07 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -3.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 51.8% higher than minimum and 46.4% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -0.3x by EV / Sales multiple

Key Financials (Download financials)

Ticker: ANIK
Share price, USD:  (+1.3%)25.77
year average price 22.99  


year start price 27.07 2023-04-21

max close price 27.65 2023-06-12

min close price 16.98 2023-09-18

current price 25.77 2024-04-19
Common stocks: 14 647 000

Dividend Yield:  0.0%
Last revenue growth (y/y):  7.5%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  8.5%
Historical growth of EBITDA:  ---
EV / Sales: 2.0x
Margin (EBITDA LTM / Revenue): -45.2%
Fundamental value created in LTM:
Market Cap ($m): 377
Net Debt ($m): -46
EV (Enterprise Value): 331
Price to Book: 1.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-02-27GlobeNewsWire

Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024

2023-12-14Zacks Investment Research

New Strong Buy Stocks for December 14th

2023-11-03Seeking Alpha

Anika Therapeutics, Inc. (ANIK) Q3 2023 Earnings Call Transcript

2023-09-01Zacks Investment Research

Down -20.42% in 4 Weeks, Here's Why You Should You Buy the Dip in Anika (ANIK)

2023-08-31Zacks Investment Research

All You Need to Know About Anika (ANIK) Rating Upgrade to Buy

2023-08-31Zacks Investment Research

Anika (ANIK) Loses -19.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

2023-08-08Zacks Investment Research

Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates

2023-05-13Seeking Alpha

Anika Therapeutics Inc. (ANIK) Q1 2023 Earnings Call Transcript

2023-05-09Zacks Investment Research

Anika Therapeutics (ANIK) Reports Q1 Loss, Tops Revenue Estimates

2023-04-19GlobeNewsWire

Anika to Issue First Quarter 2023 Financial Results on Tuesday, May 9, 2023
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ANIK ANIK ANIK ANIK ANIK ANIK
reportedCurrency USD USD USD USD USD USD
cik 898 437 898 437 898 437 898 437 898 437 898 437
fillingDate 2024-03-15 2023-11-03 2023-08-08 2023-05-09 2023-03-16 2022-11-09
acceptedDate 2024-03-15 12:20:07 2023-11-02 17:41:52 2023-08-08 17:15:17 2023-05-09 17:15:26 2023-03-16 15:37:56 2022-11-09 14:31:46
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 43M 41M 44M 38M 40M 40M
costOfRevenue 17M 17M 15M 15M 15M 17M
grossProfit 26M 25M 29M 23M 24M 23M
grossProfitRatio 0.613 0.602 0.654 0.602 0.609 0.566
researchAndDevelopmentExpenses 8M 8M 9M 8M 8M 7M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 20M 25M 24M 27M 23M 21M
otherExpenses 0 0 0 0 0 0
operatingExpenses 28M 33M 33M 35M 31M 29M
costAndExpenses 45M 49M 48M 50M 46M 46M
interestIncome 577 000 635 000 561 000 0 0 0
interestExpense 0 0 561 000 539 000 276 000 436 000
depreciationAndAmortization 4M 4M 4M 4M 4M 0
ebitda 2M -8M -81 000 -9M -7M -6M
ebitdaratio 0.047 -0.185 -0.002 -0.237 -0.168 -0.144
operatingIncome -2M -8M -4M -13M -7M -6M
operatingIncomeRatio -0.037 -0.185 -0.082 -0.331 -0.168 -0.144
totalOtherIncomeExpensesNet -62M 635 000 561 000 539 000 276 000 436 000
incomeBeforeTax -63M -7M -3M -12M -6M -5M
incomeBeforeTaxRatio -1.471 -0.170 -0.069 -0.317 -0.161 -0.133
incomeTaxExpense -204 000 -463 000 -329 000 -2M -1M -1M
netIncome -63M -7M -3M -10M -5M -4M
netIncomeRatio -1.466 -0.159 -0.062 -0.273 -0.124 -0.104
eps -4.300 -0.450 -0.190 -0.710 -0.340 -0.290
epsdiluted -4.300 -0.450 -0.190 -0.710 -0.340 -0.290
weightedAverageShsOut 15M 15M 15M 15M 15M 15M
weightedAverageShsOutDil 15M 15M 15M 15M 15M 15M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ANIK ANIK ANIK ANIK ANIK ANIK
reportedCurrency USD USD USD USD USD USD
cik 898 437 898 437 898 437 898 437 898 437 898 437
fillingDate 2024-03-15 2023-11-03 2023-08-08 2023-05-09 2023-03-16 2022-11-09
acceptedDate 2024-03-15 12:20:07 2023-11-02 17:41:52 2023-08-08 17:15:17 2023-05-09 17:15:26 2023-03-16 15:37:56 2022-11-09 14:31:46
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 73M 71M 65M 80M 86M 88M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 73M 71M 65M 80M 86M 88M
netReceivables 36M 35M 37M 31M 35M 34M
inventory 46M 44M 43M 41M 40M 37M
otherCurrentAssets 8M 8M 8M 9M 9M 9M
totalCurrentAssets 163M 157M 152M 160M 170M 168M
propertyPlantEquipmentNet 75M 75M 78M 79M 79M 78M
goodwill 8M 7M 7M 7M 7M 7M
intangibleAssets 5M 69M 71M 73M 75M 77M
goodwillAndIntangibleAssets 12M 76M 78M 80M 82M 83M
longTermInvestments 5M 0 0 0 0 0
taxAssets 1M 1M 1M 2M 1M 0
otherNonCurrentAssets 14M 19M 19M 18M 17M 18M
totalNonCurrentAssets 107M 171M 177M 179M 180M 180M
otherAssets 0 0 0 0 0 0
totalAssets 271M 328M 329M 339M 349M 348M
accountPayables 10M 8M 8M 9M 9M 8M
shortTermDebt 2M 2M 2M 2M 2M 2M
taxPayables 1M 819 000 931 000 889 000 810 000 0
deferredRevenue 1M -2M -2M 0 0 0
otherCurrentLiabilities 18M 20M 16M 18M 17M 16M
totalCurrentLiabilities 31M 28M 23M 29M 28M 26M
longTermDebt 27M 27M 28M 28M 29M 29M
deferredRevenueNonCurrent -16M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 16M 2M 3M 4M 6M 7M
otherNonCurrentLiabilities 403 999 400 000 401 000 399 000 398 000 26M
totalNonCurrentLiabilities 27M 30M 31M 33M 36M 36M
otherLiabilities 1.000 0 0 0 0 0
capitalLeaseObligations 27M 27M 30M 30M 29M 29M
totalLiabilities 58M 58M 55M 61M 64M 63M
preferredStock 0 0 0 0 0 0
commonStock 147 000 146 000 147 000 147 000 146 000 146 000
retainedEarnings 128M 191M 198M 200M 211M 216M
accumulatedOtherComprehensiveIncomeLoss -6M -7M -6M -6M -6M -7M
othertotalStockholdersEquity 90M 86M 82M 83M 81M 77M
totalStockholdersEquity 212M 270M 274M 278M 286M 285M
totalEquity 212M 270M 274M 278M 286M 285M
totalLiabilitiesAndStockholdersEquity 271M 328M 329M 339M 349M 348M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 271M 328M 329M 339M 349M 348M
totalInvestments 5M 0 0 0 0 0
totalDebt 29M 27M 30M 30M 31M 29M
netDebt -44M -43M -35M -49M -55M -59M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ANIK ANIK ANIK ANIK ANIK ANIK
reportedCurrency USD USD USD USD USD USD
cik 898 437 898 437 898 437 898 437 898 437 898 437
fillingDate 2024-03-15 2023-11-03 2023-08-08 2023-05-09 2023-03-16 2022-11-09
acceptedDate 2024-03-15 12:20:07 2023-11-02 17:41:52 2023-08-08 17:15:17 2023-05-09 17:15:26 2023-03-16 15:37:56 2022-11-09 14:31:46
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -63M -7M -3M -10M -5M -4M
depreciationAndAmortization 4M 4M 4M 4M 4M 3M
deferredIncomeTax -2M -1M -904 000 -2M -2M -1M
stockBasedCompensation 4M 4M 4M 4M 4M 4M
changeInWorkingCapital -3M 3M -14M 642 000 -2M -3M
accountsReceivables -1M 2M -6M 4M -647 000 -2M
inventory -3M -2M -3M -3M -3M -2M
accountsPayables 1M -290 000 -316 000 -713 000 1M 249 000
otherWorkingCapital 324 000 4M -4M 361 000 -311 000 1M
otherNonCashItems 64M 4M 1M 1M 2M 4M
netCashProvidedByOperatingActivities 4M 6M -8M -4M 481 000 3M
investmentsInPropertyPlantAndEquipment -2M -741 000 -1M -1M -3M -2M
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0
netCashUsedForInvestingActivites -2M -741 000 -1M -1M -3M -2M
debtRepayment 0 0 0 0 0 -231 000
commonStockIssued 335 000 0 486 000 0 0 0
commonStockRepurchased 0 -110 000 -5M 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 7000.000 -110 000 -429 000 -2M 667 000 -4M
netCashUsedProvidedByFinancingActivities 342 000 -110 000 -5M -2M 667 000 -5M
effectOfForexChangesOnCash 76 000 -54 000 27 000 30 000 -69 000 -22 000
netChangeInCash 2M 6M -15M -7M -1M -4M
cashAtEndOfPeriod 73M 71M 65M 80M 86M 88M
cashAtBeginningOfPeriod 71M 65M 80M 86M 88M 91M
operatingCashFlow 4M 6M -8M -4M 481 000 3M
capitalExpenditure -2M -741 000 -1M -1M -3M -2M
freeCashFlow 2M 6M -10M -5M -2M 1M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-03-13 ET (fiscal 2023 q4)
2023 q3
2023-11-03 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-13 ET (fiscal 2023 q1)
2022 q4
2023-03-06 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-06 ET (fiscal 2022 q2)
2022 q1
2022-05-07 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-03-13 20:05 ET
Anika Reports Fourth Quarter and Year-End 2023 Financial Results
2024-03-08 21:01 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-27 21:01 ET
Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
2024-02-13 14:00 ET
Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting
2023-11-28 14:00 ET
Anika Announces First Surgeries Performed using the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release
2023-11-07 21:05 ET
Anika to Participate in Upcoming Investor Conferences
2023-11-02 20:05 ET
Anika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the Business
2023-10-10 13:00 ET
Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023
2023-09-19 13:00 ET
Anika Announces the Full Market Release of the RevoMotion™ Reverse Shoulder Arthroplasty System during the 2023 Orthopaedic Summit: Evolving Technologies (OSET) Annual Meeting
2023-09-15 20:01 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-12 13:00 ET
Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
2023-08-17 22:20 ET
Anika Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs
2023-08-08 20:05 ET
Anika Reports Second Quarter 2023 Financial Results
2023-07-20 20:05 ET
Anika to Issue Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
2023-07-12 13:00 ET
Anika Showcases Highly Differentiated Joint Preservation and Restoration Portfolio at the 2023 AOSSM Annual Meeting
2023-05-30 20:05 ET
Anika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key Milestone
2023-05-09 20:05 ET
Anika Reports First Quarter 2023 Financial Results
2023-04-19 12:30 ET
Anika to Issue First Quarter 2023 Financial Results on Tuesday, May 9, 2023
2023-04-13 21:00 ET
Anika Enters Into Cooperation Agreement with Caligan Partners
2023-04-12 13:00 ET
Anika to Participate in the 22nd Annual Needham Virtual Healthcare Conference
2023-04-03 13:00 ET
Anika Continues to Expand Addressable Market for Tactoset® Injectable Bone Substitute with Additional 510(k) Clearance from FDA
2023-03-27 12:55 ET
Anika Files Preliminary Proxy Statement
2023-03-15 20:01 ET
Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
2023-03-08 15:00 ET
Anika Highlights Products in High Growth Segments of Joint Preservation during the 2023 AAOS Annual Meeting
2023-03-06 21:05 ET
Anika Reports Fourth Quarter and Year-End Fiscal 2022 Financial Results
2023-02-28 14:00 ET
Anika to Participate in the Canaccord Genuity Musculoskeletal Conference
2023-02-21 15:30 ET
Anika to Issue Fourth Quarter and Year-End 2022 Financial Results on Monday, March 6, 2023
2023-02-21 15:00 ET
Anika Issues Statement
2023-02-21 13:00 ET
Caligan Partners Issues Open Letter to Anika Board
2023-02-13 13:30 ET
Anika Announces First Surgeries Performed Using the New RevoMotion™ Reverse Shoulder Arthroplasty System and Commences Limited Market Release in the United States
2022-11-08 21:05 ET
Anika Reports Third Quarter Fiscal 2022 Financial Results
2022-11-01 12:00 ET
Anika’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study
2022-10-25 13:25 ET
Anika to Issue Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
2022-09-12 20:01 ET
Anika Announces First Surgeries Performed Using the X-Twist™ Fixation System and Commences Limited Market Release
2022-08-03 20:05 ET
Anika Reports Second Quarter Fiscal 2022 Financial Results
2022-07-27 13:15 ET
Anika Receives the ACE Award for Cutting-Edge Innovation for Tactoset® Injectable Bone Substitute from the American Orthopedic Society for Sports Medicine
2022-07-12 21:05 ET
Anika to Issue Second Quarter 2022 Financial Results on Wednesday, August 3, 2022
2022-06-10 13:27 ET
Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
2022-05-20 11:00 ET
Anika Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio
2022-05-13 21:00 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-05-09 20:05 ET
Anika to Participate in the UBS Global Healthcare Conference 2022
2022-05-05 20:05 ET
Anika Reports First Quarter Fiscal 2022 Financial Results
2022-04-15 21:00 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-04-07 20:05 ET
Anika to Issue First Quarter 2022 Financial Results on Thursday, May 5, 2022
2022-04-04 20:05 ET
Anika to Participate in the 21st Annual Needham Virtual Healthcare Conference
2022-03-23 12:30 ET
Anika to Showcase its Transformation into a Global Leader in Joint Preservation during the 2022 AAOS Annual Meeting
2022-03-15 23:00 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-03-10 21:05 ET
Anika to Participate in the Canaccord Genuity Musculoskeletal Conference
2022-03-08 21:05 ET
Anika Reports Fourth Quarter and Year-End 2021 Financial Results
2022-02-11 23:50 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-02-08 21:01 ET
Anika to Issue Fourth Quarter and Year-End 2021 Financial Results on Tuesday, March 8, 2022
2021-12-10 22:00 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-11-18 21:01 ET
Anika to Participate in Upcoming Investor Conferences
2021-11-04 20:05 ET
Anika Reports Third Quarter 2021 Financial Results
2021-11-01 13:00 ET
Anika Appoints Sheryl Conley to Board of Directors
2021-10-18 13:00 ET
Anika to Issue Third Quarter 2021 Financial Results on Thursday, November 4, 2021
2021-09-30 13:00 ET
Anika Launches the WristMotion® Total Wrist Arthroplasty System at the American Society for Surgery of the Hand Annual Meeting
2021-09-14 13:00 ET
Tactoset® Injectable Bone Substitute Now FDA Cleared for Hardware Augmentation
2021-09-07 14:00 ET
Anika to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
2021-09-01 14:05 ET
Anika to Debut Joint Preservation Portfolio at the 2021 AAOS Annual Meeting
2021-08-05 20:05 ET
Anika Reports Second Quarter 2021 Financial Results
2021-07-19 14:00 ET
Anika to Issue Second Quarter 2021 Financial Results on Thursday, August 5, 2021
2021-07-01 13:00 ET
First Anika WristMotion® Total Wrist Arthroplasty Surgery Performed
2021-06-03 12:00 ET
Anika Hosts 2021 Virtual Investor Day
2021-05-13 15:00 ET
Anika to Host its 2021 Virtual Investor Day on June 3, 2021
2021-05-06 20:05 ET
Anika Reports First Quarter 2021 Financial Results
2021-05-04 14:30 ET
Anika to Participate in Upcoming Virtual Investor Conferences
2021-04-15 21:15 ET
Anika to Issue First Quarter 2021 Financial Results on Thursday, May 6, 2021
2021-04-05 13:25 ET
Anika to Participate in the 20th Annual Needham Virtual Healthcare Conference
2021-03-11 17:15 ET
Anika to Participate in the Sidoti Spring Virtual Investor Conference
2021-03-04 21:05 ET
Anika Reports Fourth Quarter and Year-End 2020 Financial Results
2021-02-09 20:00 ET
Anika to Issue Fourth Quarter and Year-End 2020 Financial Results on Thursday, March 4, 2021
2020-11-04 21:05 ET
Anika Reports Third-Quarter 2020 Financial Results
2020-10-22 20:05 ET
Anika to Issue Third Quarter 2020 Financial Results and Business Highlights on Wednesday, November 4, 2020
2020-10-21 20:05 ET
Anika Announces FDA 510(k) Clearance for its WristMotion® Total Arthroplasty System for the Replacement of Painful Wrist Joints
2020-09-08 20:53 ET
Anika Announces Appointment of Jack Henneman and Stephen Richard to Board of Directors
2020-09-03 18:34 ET
Anika to Participate in Upcoming Virtual Investor Conferences
2020-08-05 20:09 ET
Anika Appoints Michael Levitz as Chief Financial Officer
2020-07-30 20:05 ET
Anika Reports Second Quarter 2020 Financial Results
2020-07-20 11:00 ET
Anika To Launch Six FDA-Cleared Sports Medicine and Extremities Products in Third Quarter of 2020
2020-07-16 20:05 ET
Anika to Issue Second Quarter 2020 Financial Results and Business Highlights on Thursday, July 30
2020-06-02 20:05 ET
Anika Announces Planned CFO Transition
2020-05-12 20:05 ET
Anika to Participate in 2020 UBS Virtual Global Healthcare Conference
2020-05-07 20:05 ET
Anika Reports First Quarter 2020 Financial Results
2020-04-27 12:30 ET
Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer
2020-04-23 20:05 ET
Anika to Issue First Quarter 2020 Financial Results and Business Highlights on Thursday, May 7
2020-04-08 20:05 ET
Anika Takes Actions to Strengthen Liquidity in Light of COVID-19
2020-03-04 13:30 ET
Anika Appoints David Colleran as General Counsel
2020-02-20 21:05 ET
Anika Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-12 21:05 ET
Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO
2020-02-06 21:05 ET
CORRECTING and REPLACING Anika to Issue Fourth-Quarter and Full-Year 2019 Financial Results and Business Highlights on Thursday, February 20
2020-02-03 21:30 ET
Anika Therapeutics Closes Acquisition of Arthrosurface
2020-01-29 21:30 ET
Anika Therapeutics Mourns the Sudden Passing of Joseph Darling, President and Chief Executive Officer
2020-01-24 21:05 ET
Anika Therapeutics Closes Acquisition of Parcus Medical
2020-01-13 20:00 ET
Sale of Global Leader in Joint Preservation Incubated at Primo Medical Group
2020-01-06 13:30 ET
Anika Therapeutics to Acquire Parcus Medical and Arthrosurface
2019-12-10 13:30 ET
Anika Commences Full U.S. Commercial Launch of TACTOSET Bone Repair Therapy at Orthopaedic Summit 2019: Evolving Techniques
2019-11-15 13:30 ET
Anika Therapeutics Announces Participation in MEDICA International Trade Fair and International Cartilage Regeneration and Joint Preservation Society Focus Meeting
2019-10-24 20:05 ET
Anika Reports Third Quarter 2019 Financial Results
2019-10-16 12:30 ET
Anika to Showcase Joint Preservation and Restoration Portfolio at the Annual Scientific Meeting of the International Society for Hip Arthroscopy
2019-10-14 12:30 ET
Anika Appoints Mira Leiwant as Vice President of Regulatory Affairs, Quality, and Clinical Affairs
2019-10-10 20:05 ET
Anika to Issue Third-quarter 2019 Financial Results and Business Highlights on Thursday, October 24
2019-10-04 12:30 ET
Anika to Showcase Joint Preservation and Restoration Portfolio at the 2019 World Congress of the International Cartilage Regeneration and Joint Preservation Society
2019-09-18 12:30 ET
Anika Commences U.S. Commercial Launch of TACTOSET Bone Repair Therapy Under Its New U.S. Hybrid Commercial Model

SEC forms

Show financial reports only

SEC form 10
2024-03-15 00:00 ET
Anika Therapeutics published news for 2023 q4
SEC form 8
2024-03-13 16:10 ET
Anika Therapeutics published news for 2023 q4
SEC form 8
2024-03-13 16:10 ET
Anika Therapeutics reported for 2023 q4
SEC form 10
2023-11-03 00:00 ET
Anika Therapeutics published news for 2023 q3
SEC form 10
2023-11-02 17:41 ET
Anika Therapeutics published news for 2023 q3
SEC form 8
2023-11-02 16:11 ET
Anika Therapeutics reported for 2023 q3
SEC form 10
2023-08-08 17:15 ET
Anika Therapeutics reported for 2023 q2
SEC form 6
2023-08-08 16:11 ET
Anika Therapeutics published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Anika Therapeutics published news for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Anika Therapeutics published news for 2023 q2
SEC form 6
2023-06-21 16:50 ET
Anika Therapeutics published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Anika Therapeutics published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Anika Therapeutics published news for 2023 q1
SEC form 10
2023-03-16 00:00 ET
Anika Therapeutics reported for 2022 q4
SEC form 8
2023-03-06 00:00 ET
Anika Therapeutics reported for 2022 q4
SEC form 10
2022-11-09 00:00 ET
Anika Therapeutics reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Anika Therapeutics reported for 2022 q3
SEC form 10
2022-08-04 00:00 ET
Anika Therapeutics reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Anika Therapeutics reported for 2022 q2
SEC form 10
2022-05-06 00:00 ET
Anika Therapeutics reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Anika Therapeutics reported for 2022 q1
SEC form 10
2022-03-11 00:00 ET
Anika Therapeutics published news for 2021 q4
SEC form 8
2022-03-08 00:00 ET
Anika Therapeutics published news for 2021 q4
SEC form 10
2021-11-05 00:00 ET
Anika Therapeutics published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Anika Therapeutics published news for 2021 q3
SEC form 10
2021-08-06 00:00 ET
Anika Therapeutics published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Anika Therapeutics published news for 2021 q2
SEC form 10
2021-05-07 00:00 ET
Anika Therapeutics published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Anika Therapeutics published news for 2021 q1